SCHEMBL20173512

SCHEMBL20173512

CC(C)[C@H](NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)c1ccccc1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
FURIN P09958 4/20 0.43
MAPT P10636 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
KDM4E B2RXH2 2/20 0.42
PAX8 Q06710 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
BACE1 P56817 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SIRT2 Q8IXJ6 4/20 0.40
SIRT1 Q96EB6 3/20 0.40
SIRT3 Q9NTG7 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16946400 0.90 CA2 (0.53) CA1CA2FURINMAPTTDP1
SCHEMBL17541381 0.89 CA2 (0.50) CA1CA2FURINMAPTTDP1
SCHEMBL17541380 0.89 CA2 (0.50) CA1CA2FURINMAPTTDP1
SCHEMBL23880504 0.89 CA2 (0.51) CA1CA2FURINMAPTTDP1
SCHEMBL17541357 0.87 CA2 (0.47) CA1CA2FURINMAPTTDP1
SCHEMBL17541356 0.87 CA2 (0.47) CA1CA2FURINMAPTTDP1
SCHEMBL17902993 0.87 CA2 (0.46) CA1CA2FURINMMP1MMP3
SCHEMBL20158426 0.87 CA2 (0.46) CA1CA2FURINMMP1MMP3
SCHEMBL14012279 0.87 CA2 (0.46) CA1CA2FURINMMP1MMP3
SCHEMBL12283259 0.87 CA2 (0.46) CA1CA2FURINMMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10967068-B2 Stability-modulating linkers for use with antibody drug conjugates PFIZER INC. (US) 2021-04-06 US disclosed
US-20180140714-A1 STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES PFIZER INC. (US) 2018-05-24 US disclosed
US-20180140714-A1 STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES PFIZER INC. (US) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10967068-B2 Stability-modulating linkers for use with antibody drug conjugates FCGR2A, FCGRT, FCGR1A CA1 2758/4885CA2 4520/4885FURIN 600/4885
US-20180140714-A1 STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES FCGR2A, FCGRT, FCGR1A CA1 2758/4885CA2 4520/4885FURIN 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.